Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INSR | P06213 | 1/20 | 0.61 |
| ▸ | NPY2R | P49146 | 6/20 | 0.57 |
| ▸ | MC4R | P32245 | 2/20 | 0.55 |
| ▸ | MC1R | Q01726 | 2/20 | 0.55 |
| ▸ | MC3R | P41968 | 1/20 | 0.55 |
| ▸ | F11 | P03951 | 1/20 | 0.55 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.54 |
| ▸ | KCNMB4 | Q86W47 | 1/20 | 0.54 |
| ▸ | KLK7 | P49862 | 2/20 | 0.53 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.52 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.52 |
| ▸ | RAMP1 | O60894 | 1/20 | 0.52 |
| ▸ | RAMP2 | O60895 | 1/20 | 0.52 |
| ▸ | RAMP3 | O60896 | 1/20 | 0.52 |
| ▸ | CALCR | P30988 | 1/20 | 0.52 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.52 |
| ▸ | ACE | P12821 | 1/20 | 0.52 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.52 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.52 |
| ▸ | TEAD1 | P28347 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29965049 | 0.95 | INSR (0.62) | INSRNPY2RMC4RMC1RMC3R | |
| SCHEMBL29387159 | 0.95 | INSR (0.60) | INSRNPY2RMC4RMC1RMC3R | |
| SCHEMBL31736960 | 0.93 | INSR (0.59) | INSRNPY2RMC4RMC1RMC3R | |
| SCHEMBL29964088 | 0.90 | INSR (0.56) | INSRNPY2RMC4RMC1RMC3R | |
| SCHEMBL29387178 | 0.86 | INSR (0.59) | INSRNPY2RMC4RMC1RMC3R | |
| SCHEMBL29904330 | 0.82 | INSR (0.58) | INSRNPY2RMC4RMC1RMC3R | |
| SCHEMBL29390185 | 0.81 | MC4R (0.63) | INSRNPY2RMC4RMC1RMC3R | |
| SCHEMBL29389145 | 0.80 | MC4R (0.65) | INSRNPY2RMC4RMC1RMC3R | |
| SCHEMBL29393563 | 0.79 | F11 (0.56) | INSRNPY2RMC4RMC1RMC3R | |
| SCHEMBL29412264 | 0.79 | KCNA3 (0.57) | INSRNPY2RMC4RMC1RMC3R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260043020-A1 | BINDING MEMBERS WITH ALTERED DIVERSITY SCAFFOLD DOMAINS | Maxion Therapeutics Limited (GB) | 2026-02-12 | — | — | US | claimed |
| US-12606937-B2 | Humanized antibodies with ultralong complementary determining regions | TAURUS BIOSCIENCES, LLC (US) | 2026-04-21 | — | — | US | disclosed |
| US-20260104424-A1 | METHODS, SYSTEMS AND KITS FOR IDENTIFYING BIOACTIVE COMPOUNDS AND THERAPEUTIC METHODS AND COMPOSITIONS | UNIV JOHNS HOPKINS (US) | 2026-04-16 | — | — | US | disclosed |
| US-20260043020-A1 | BINDING MEMBERS WITH ALTERED DIVERSITY SCAFFOLD DOMAINS | Maxion Therapeutics Limited (GB) | 2026-02-12 | — | — | US | disclosed |
| WO-2025241040-A1 | PEPTIDES DERIVED FROM THE VENOM OF THE HETEROCTENUS JUNCEUS SCORPION, ITS VARIANTS, COMPOSITIONS, METHODS AND USES | BLUE SCORPION GROUP INC (US) | 2025-11-27 | — | — | WO | disclosed |
| US-12433949-B2 | Sustained release delivery systems comprising traceless linkers | NOVARTIS AG (CH) | 2025-10-07 | — | — | US | disclosed |
| EP-4604984-A1 | INHIBITORS | Zealand Pharma A/S (DK) | 2025-08-27 | — | — | EP | disclosed |
| US-20250230144-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2025-07-17 | — | — | US | disclosed |
| US-20250213627-A1 | RECOMBINANT MICROORGANISM-BASED METHODS AND COMPOSITIONS FOR TREATMENT OF DISEASE | BAYLOR COLLEGE OF MEDICINE (US) | 2025-07-03 | — | — | US | disclosed |
| US-20240374689-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. | 2024-11-14 | — | — | US | disclosed |
| WO-2022266494-A1 | RIPPLED ANTIPARALLEL CROSS-BETA DIMERS AND RELATED MATERIALS, COMPOSITIONS AND METHODS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-12-22 | — | — | WO | disclosed |
| US-11530493-B2 | Humanized antibodies with ultralong complementary determining regions | TAURUS BIOSCIENCES, LLC (US) | 2022-12-20 | — | — | US | disclosed |
| US-11484576-B2 | Methods of promoting corticospinal neuronal outgrowth in neuronal lesions using a pro-regenerative human osteopontin fragment | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2022-11-01 | — | — | US | disclosed |
| US-20220324836-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2022-10-13 | — | — | US | disclosed |
| WO-2022200374-A1 | KV1.3 BLOCKERS | ZEALAND PHARMA A/S (DK) | 2022-09-29 | — | — | WO | disclosed |
| US-20220251151-A1 | KV1.3 BLOCKERS | ZEALAND PHARMA A/S (DK) | 2022-08-11 | — | — | US | disclosed |
| EP-4031162-A1 | KV1.3 BLOCKERS | Zealand Pharma A/S (DK) | 2022-07-27 | — | — | EP | disclosed |
| US-11331393-B2 | Renal-homing peptide conjugates and methods of use thereof | Blaze Bioscience, Inc. (US) | 2022-05-17 | — | — | US | disclosed |
| US-11292820-B2 | KV1.3 blockers | ZEALAND PHARMA A/S (DK) | 2022-04-05 | — | — | US | disclosed |
| US-11278595-B2 | Peptides comprising non-natural amino acids and methods of making and using the same | LONGEVITY BIOTECH, INC. (US) | 2022-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12606937-B2 | Humanized antibodies with ultralong complementary determining regions | IGLV6-57, FCGR3B, VSIR | INSR 1021/4885NPY2R 340/4885MC4R 1349/4885 |
| US-20220324836-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | KCNJ4, KCNK4, KCNQ4 | INSR 245/4885NPY2R 537/4885MC4R 1206/4885 |
| US-20250230144-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | KCNJ4, KCNK4, KCNQ4 | INSR 245/4885NPY2R 537/4885MC4R 1206/4885 |
| US-11331393-B2 | Renal-homing peptide conjugates and methods of use thereof | CXCL12, ATP6V1B1, VIP | INSR 1596/4885NPY2R 674/4885MC4R 1472/4885 |
| US-20260104424-A1 | METHODS, SYSTEMS AND KITS FOR IDENTIFYING BIOACTIVE COMPOUNDS AND THERAPEUTIC METHODS AND COMPOSITIONS | VIP, SYNCRIP, MTREX | INSR 2291/4885NPY2R 832/4885MC4R 2083/4885 |
| US-12433949-B2 | Sustained release delivery systems comprising traceless linkers | ABCB11, ABCB1, GHRHR | INSR 782/4885NPY2R 633/4885MC4R 3990/4885 |
| US-11278595-B2 | Peptides comprising non-natural amino acids and methods of making and using the same | APLNR, SCTR, GIPR | INSR 23/4885NPY2R 183/4885MC4R 451/4885 |
| US-11292820-B2 | KV1.3 blockers | KCNA3, KCNK3, KCNN3 | INSR 2284/4885NPY2R 1696/4885MC4R 1538/4885 |
| US-20260043020-A1 | BINDING MEMBERS WITH ALTERED DIVERSITY SCAFFOLD DOMAINS | VSIG8, CDR2, VSIR | INSR 3832/4885NPY2R 3884/4885MC4R 4508/4885 |
| US-20220251151-A1 | KV1.3 BLOCKERS | KCNA3, KCNK3, KCNN3 | INSR 2284/4885NPY2R 1696/4885MC4R 1538/4885 |
| US-20240374689-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | SCTR, GIPR, APLNR | INSR 15/4885NPY2R 129/4885MC4R 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.